FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
This is an open label, single-arm phase II, multi-institutional trial to evaluate the
efficacy and safety of the combination of nab-paclitaxel and FOLFOX (FOLFOX-A) as first line
therapy for patients diagnosed with histologically-confirmed advanced gastric/GEJ
adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Al B. Benson, III, MD
Collaborators:
Big Ten Cancer Research Consortium Celgene Corporation